We'll likely be getting important color on the AD TLR. An overall reduction in % cognitive and functional decline will be crucial to compare to Lecanemab, but stratification on our pre-defined cohorts - dose, S1 and APOE status, and cognitive baseline - will be of great interest at CTAD. And regulators. It's where precision medicine meets the road and hopefully there are some good correlation coeffs.
Market Data 
Markets 
AI
